<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03668171</url>
  </required_header>
  <id_info>
    <org_study_id>KY20172049-1</org_study_id>
    <nct_id>NCT03668171</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stem Cell Transplantation for Acute-on-chronic Liver Failure</brief_title>
  <official_title>Mesenchymal Stem Cell Transplantation for Acute-on-chronic Liver Failure, a Randomized, Double Blind, Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital of Digestive Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital of Digestive Diseases</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mesenchymal stem cells (MSC) has been reported to improved outcomes of acute-on-chronic liver
      failure(ACLF). More randomization controlled studies are needed to confirm the effect of MSC
      treatment for ACLF. This study aimed to investigate the efficacy of mesenchymal stem cells in
      ACLF patients. This study is an double-blind multicenter randomized and placebo-controlled
      study. Patients with with ACLF will be randomly assigned to receive MSC treatment
      (experimental) or standard medical treatment (control). Three times of MSC infusion
      (0.1-1x10E6cells/kg body weight) via peripheral vein will be given to the experimental group
      (once per week). The primary outcome is 12 week mortality. Secondary outcomes are clinical
      remission rate and changes of liver function indices and liver function scores.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Randomization will be blinded to participant, care provider, investigator and outcome assessors.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: 12 week mortality rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>mortality rate assessed at week 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical remission rate at week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Clinical remission define as: significant improvement of symptoms and resolution of hepatoencephalopathy; TBIL decrease to below 5 times of ULN，PTA&gt;40% or INR&lt;1.6</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Acute-On-Chronic Liver Failure</condition>
  <arm_group>
    <arm_group_label>MSC group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mesenchymal stem cell transplantation via peripheral vein: 0.1-1x10E6 MSCs/kg body weight administered via peripheral vein at week 0, 1, 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo infusions (placebo infusion differs from the experimental infusion in only that placebo has no mesenchymal stem cells) will be administered via peripheral vein at week 0, 1, 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>mesenchymal stem cell transplantation or placebo infusion via peripheral vein</intervention_name>
    <description>0.1-1x10E6 MSCs/kg body weight will be administered via peripheral vein for 3 times at week 0, 4 and 8 mesenchymal stem cell mesenchymal stem cell infusion produced by Cell products of National Engineering Research Center(short for CPNERC), Tianjin, China For control group, placebo infusions will be given to the participants at the same time points</description>
    <arm_group_label>MSC group</arm_group_label>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18-70 years old

          -  Meeting the criteria of ACLF defined as: 1. definitive chronic liver diseases, acute
             decompensation within 4 weeks; 2. Significant GI symptom as such fatigue, jaundice,;
             3. total bilirubin (TBIL) ≥170 µmo1/L or daily increase of TBIL ≥17.1 µmo1/L; 4.
             PTA≤40% or INR≥ 1.5; 5. Decompensation of liver functions such as ascites or
             hepatoencephalopathy;

          -  MELD score between 17-30. (MELD(i) = 0.957 × ln(Cr) + 0.378 × ln(bilirubin) + 1.120 ×
             ln(INR) + 0.643)

          -  Chronic liver disease with definitive etiology such as viral hepatitis, alcohol liver
             disease, drug induced liver injury or autoimmune liver diseases

          -  Informed consent

        Exclusion Criteria:

          -  Sever complications with 30 days ( GI bleeding, severe infection)；

             --liver cancer or other malignancies

          -  patients on liver transplantation list

          -  patients with uncontrolled infections

          -  severe renal failure

          -  Severe chronic obstructive pulmonary disease COPD (GOLD III-IV)

          -  Extrahepatic cholanstasis patients due to biliary obstruction.

          -  HIV infection

          -  Pregnant or breast-feeding females.

          -  Enrolled in other clinical trials with 3 months

          -  other conditions considered inappropriate for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ying Han, MD</last_name>
    <phone>862984771539</phone>
    <email>guochc@fmmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Changcun Guo</last_name>
    <phone>13991900180</phone>
    <email>guochc@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Changcun Guo</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Changcun Guo</last_name>
      <phone>13991900180</phone>
      <email>guochc@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 10, 2018</study_first_submitted>
  <study_first_submitted_qc>September 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2018</study_first_posted>
  <last_update_submitted>September 10, 2018</last_update_submitted>
  <last_update_submitted_qc>September 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xijing Hospital of Digestive Diseases</investigator_affiliation>
    <investigator_full_name>Han Ying</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>Acute-On-Chronic Liver Failure, mesenchymal stem cell,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
    <mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Study protocol, statistical analysis processes and clinical data of individual participants will be shared.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>within 12 months after the study completion and before publications of the findings.</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

